3.71
-0.11(-2.88%)
Currency In USD
| Previous Close | 3.82 |
| Open | 3.78 |
| Day High | 4.01 |
| Day Low | 3.68 |
| 52-Week High | 7 |
| 52-Week Low | 2.16 |
| Volume | 67,051 |
| Average Volume | 97,456 |
| Market Cap | 34.24M |
| PE | -0.59 |
| EPS | -6.3 |
| Moving Average 50 Days | 3.46 |
| Moving Average 200 Days | 3.3 |
| Change | -0.11 |
If you invested $1000 in SAB Biotherapeutics, Inc. (SABS) since IPO date, it would be worth $36.55 as of January 03, 2025 at a share price of $3.71. Whereas If you bought $1000 worth of SAB Biotherapeutics, Inc. (SABS) shares 3 years ago, it would be worth $43.65 as of January 03, 2025 at a share price of $3.71.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
GlobeNewswire Inc.
Nov 06, 2024 10:05 PM GMT
Company announced completed Phase 1 enrollment for SAB-142 with no observation of serum sickness. The company remains on track for a topline Phase 1 data readout by the end of the year. MIAMI, Nov. 06, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
GlobeNewswire Inc.
Oct 31, 2024 11:00 AM GMT
MIAMI, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
GlobeNewswire Inc.
Sep 13, 2024 11:00 AM GMT
MIAMI, Sept. 13, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset